Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alfaprostol is a synthetic small molecule analogue of prostaglandin F2α (PGF2α) specifically developed for use in veterinary reproductive medicine. It functions as a potent luteolytic agent by acting as an agonist at the prostaglandin F (FP) receptor. This action induces the regression of the corpus luteum, leading to a rapid decline in systemic progesterone levels and the subsequent initiation of the estrous cycle or the induction of parturition. Developed by Xiamen Origin Biotech, alfaprostol is utilized in livestock species such as cattle, horses, and swine to manage reproductive cycles, synchronize estrus, and treat conditions such as persistent corpus luteum or silent heat.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alfaprostol.